Yigal Nochomovitz
Stock Analyst at Citigroup
(3.26)
# 1,194
Out of 4,435 analysts
192
Total ratings
38.64%
Success rate
4.06%
Average return
Main Sectors:
Top Industries:
39 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Maintains: Buy | $7 → $13 | $8.69 | +49.60% | 2 | May 31, 2024 | |
| CALT Calliditas Therapeutics AB (publ) | Downgrades: Neutral | $39 | $39.65 | -1.64% | 2 | May 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $89 → $84 | $53.74 | +56.31% | 17 | May 23, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $32 → $30 | $19.27 | +55.68% | 5 | May 9, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $67 → $60 | $39.25 | +52.87% | 11 | May 8, 2024 | |
| OVID Ovid Therapeutics | Maintains: Neutral | $4 → $3.5 | $3.06 | +14.38% | 5 | May 7, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Buy | $15 → $14 | $8.99 | +55.73% | 5 | May 7, 2024 | |
| ZYME Zymeworks | Maintains: Buy | $17 → $16 | $8.48 | +88.68% | 9 | May 3, 2024 | |
| ARDX Ardelyx | Maintains: Buy | $13 → $14 | $6.86 | +104.08% | 7 | May 3, 2024 | |
| PRQR ProQR Therapeutics | Maintains: Neutral | $1.8 → $2 | $1.95 | +2.56% | 3 | Apr 18, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Buy | $34 | $15.29 | +122.37% | 1 | Apr 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $40 → $60 | $36.55 | +64.16% | 2 | Mar 21, 2024 | |
| MGNX MacroGenics | Maintains: Buy | $13 → $25 | $4.09 | +511.25% | 9 | Mar 11, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Buy | $3 → $4 | $0.98 | +309.08% | 4 | Mar 7, 2024 | |
| ZLAB Zai Lab | Maintains: Buy | $123 → $66 | $17.78 | +271.20% | 7 | Feb 29, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $160 → $195 | $160.05 | +21.84% | 1 | Feb 27, 2024 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $30 | $19.41 | +54.56% | 1 | Feb 20, 2024 | |
| APLT Applied Therapeutics | Maintains: Buy | $5 → $7 | $4.28 | +63.55% | 4 | Feb 16, 2024 | |
| ARVN Arvinas | Downgrades: Neutral | $36 → $55 | $33.14 | +65.96% | 7 | Feb 15, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $40 → $48 | $38.81 | +23.68% | 5 | Feb 8, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $9.68 | +106.61% | 1 | Jan 30, 2024 | |
| BMEA Biomea Fusion | Reiterates: Buy | $90 | $10.52 | +755.51% | 6 | Dec 8, 2023 | |
| BGNE BeiGene | Maintains: Buy | $290 → $285 | $148.85 | +91.47% | 3 | Oct 26, 2023 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $25 → $8 | $3.86 | +107.25% | 8 | Oct 17, 2023 | |
| GRTX Galera Therapeutics | Maintains: Neutral | $0.4 → $0.25 | $0.22 | +16.23% | 2 | Aug 29, 2023 | |
| RCUS Arcus Biosciences | Maintains: Buy | $41 → $44 | $15.07 | +191.97% | 6 | Aug 24, 2023 | |
| ATRA Atara Biotherapeutics | Maintains: Sell | $2 → $1.4 | $0.56 | +149.60% | 7 | Aug 21, 2023 | |
| MRUS Merus | Maintains: Buy | $48 → $46 | $53.24 | -13.60% | 12 | Aug 10, 2023 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $130 → $133 | $40.14 | +231.34% | 10 | Jun 7, 2023 | |
| LXRX Lexicon Pharmaceuticals | Maintains: Buy | $6 → $8 | $1.70 | +370.59% | 5 | May 31, 2023 | |
| UBX Unity Biotechnology | Maintains: Buy | $5 → $6 | $1.55 | +287.10% | 6 | May 26, 2023 | |
| CLLS Cellectis | Maintains: Buy | $24 → $16 | $2.71 | +490.41% | 2 | Apr 5, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $9 → $10 | $3.68 | +171.74% | 3 | Mar 2, 2023 | |
| PROK ProKidney | Initiates: Buy | $16 | $3.48 | +359.77% | 1 | Oct 14, 2022 | |
| OPT Opthea | Maintains: Buy | $45 → $44 | $2.84 | +1,449.30% | 2 | Sep 16, 2022 | |
| IPHA Innate Pharma | Maintains: Buy | $16 → $12 | $2.74 | +337.96% | 1 | Sep 16, 2022 | |
| CRBU Caribou Biosciences | Maintains: Buy | $39 → $38 | $2.88 | +1,219.44% | 4 | Aug 29, 2022 | |
| STTK Shattuck Labs | Initiates: Buy | $13 | $7.38 | +76.15% | 1 | Jun 1, 2022 | |
| PBYI Puma Biotechnology | Maintains: Buy | n/a | $3.85 | - | 5 | Mar 1, 2019 |
Summit Therapeutics
May 31, 2024
Maintains: Buy
Price Target: $7 → $13
Current: $8.69
Upside: +49.60%
Calliditas Therapeutics AB (publ)
May 31, 2024
Downgrades: Neutral
Price Target: $39
Current: $39.65
Upside: -1.64%
CRISPR Therapeutics AG
May 23, 2024
Maintains: Buy
Price Target: $89 → $84
Current: $53.74
Upside: +56.31%
Syndax Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $19.27
Upside: +55.68%
Apellis Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $67 → $60
Current: $39.25
Upside: +52.87%
Ovid Therapeutics
May 7, 2024
Maintains: Neutral
Price Target: $4 → $3.5
Current: $3.06
Upside: +14.38%
ORIC Pharmaceuticals
May 7, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $8.99
Upside: +55.73%
Zymeworks
May 3, 2024
Maintains: Buy
Price Target: $17 → $16
Current: $8.48
Upside: +88.68%
Ardelyx
May 3, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $6.86
Upside: +104.08%
ProQR Therapeutics
Apr 18, 2024
Maintains: Neutral
Price Target: $1.8 → $2
Current: $1.95
Upside: +2.56%
LENZ Therapeutics
Apr 10, 2024
Initiates: Buy
Price Target: $34
Current: $15.29
Upside: +122.37%
IDEAYA Biosciences
Mar 21, 2024
Maintains: Buy
Price Target: $40 → $60
Current: $36.55
Upside: +64.16%
MacroGenics
Mar 11, 2024
Maintains: Buy
Price Target: $13 → $25
Current: $4.09
Upside: +511.25%
Rigel Pharmaceuticals
Mar 7, 2024
Maintains: Buy
Price Target: $3 → $4
Current: $0.98
Upside: +309.08%
Zai Lab
Feb 29, 2024
Maintains: Buy
Price Target: $123 → $66
Current: $17.78
Upside: +271.20%
Krystal Biotech
Feb 27, 2024
Maintains: Buy
Price Target: $160 → $195
Current: $160.05
Upside: +21.84%
ArriVent BioPharma
Feb 20, 2024
Initiates: Buy
Price Target: $30
Current: $19.41
Upside: +54.56%
Applied Therapeutics
Feb 16, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.28
Upside: +63.55%
Arvinas
Feb 15, 2024
Downgrades: Neutral
Price Target: $36 → $55
Current: $33.14
Upside: +65.96%
Arcturus Therapeutics Holdings
Feb 8, 2024
Maintains: Buy
Price Target: $40 → $48
Current: $38.81
Upside: +23.68%
Olema Pharmaceuticals
Jan 30, 2024
Initiates: Buy
Price Target: $20
Current: $9.68
Upside: +106.61%
Biomea Fusion
Dec 8, 2023
Reiterates: Buy
Price Target: $90
Current: $10.52
Upside: +755.51%
BeiGene
Oct 26, 2023
Maintains: Buy
Price Target: $290 → $285
Current: $148.85
Upside: +91.47%
Aldeyra Therapeutics
Oct 17, 2023
Maintains: Buy
Price Target: $25 → $8
Current: $3.86
Upside: +107.25%
Galera Therapeutics
Aug 29, 2023
Maintains: Neutral
Price Target: $0.4 → $0.25
Current: $0.22
Upside: +16.23%
Arcus Biosciences
Aug 24, 2023
Maintains: Buy
Price Target: $41 → $44
Current: $15.07
Upside: +191.97%
Atara Biotherapeutics
Aug 21, 2023
Maintains: Sell
Price Target: $2 → $1.4
Current: $0.56
Upside: +149.60%
Merus
Aug 10, 2023
Maintains: Buy
Price Target: $48 → $46
Current: $53.24
Upside: -13.60%
Ultragenyx Pharmaceutical
Jun 7, 2023
Maintains: Buy
Price Target: $130 → $133
Current: $40.14
Upside: +231.34%
Lexicon Pharmaceuticals
May 31, 2023
Maintains: Buy
Price Target: $6 → $8
Current: $1.70
Upside: +370.59%
Unity Biotechnology
May 26, 2023
Maintains: Buy
Price Target: $5 → $6
Current: $1.55
Upside: +287.10%
Cellectis
Apr 5, 2023
Maintains: Buy
Price Target: $24 → $16
Current: $2.71
Upside: +490.41%
Fate Therapeutics
Mar 2, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $3.68
Upside: +171.74%
ProKidney
Oct 14, 2022
Initiates: Buy
Price Target: $16
Current: $3.48
Upside: +359.77%
Opthea
Sep 16, 2022
Maintains: Buy
Price Target: $45 → $44
Current: $2.84
Upside: +1,449.30%
Innate Pharma
Sep 16, 2022
Maintains: Buy
Price Target: $16 → $12
Current: $2.74
Upside: +337.96%
Caribou Biosciences
Aug 29, 2022
Maintains: Buy
Price Target: $39 → $38
Current: $2.88
Upside: +1,219.44%
Shattuck Labs
Jun 1, 2022
Initiates: Buy
Price Target: $13
Current: $7.38
Upside: +76.15%
Puma Biotechnology
Mar 1, 2019
Maintains: Buy
Price Target: n/a
Current: $3.85
Upside: -